Medical Coverage Policy

Stem Cell Therapy for Orthopaedic Applications

Table of Contents

Overview .............................................................. 1
Coverage Policy ................................................... 1
General Background ............................................ 2
Coding/Billing Information .................................... 8
References .......................................................... 8

Related Coverage Resources

Autologous Platelet-Derived Growth Factors (Platelet-Rich Plasma [PRP])
Bone, Cartilage, and Ligament Graft Substitutes

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses stem cell therapy for orthopaedic applications, in particular mesenchymal stem cells (MSCs). MSCs have been proposed as a type of regenerative therapy. Regenerative therapy is considered an emerging field of medicine focusing on repair, replacement, or regeneration of cells and tissues. MSCs are found in a variety of tissues and have the ability to rapidly proliferate and differentiate to musculoskeletal tissue, including bone and cartilage.

For the intent of this Coverage Policy “stem cell therapy” refers to mesenchymal stem cells harvested from bone marrow, adipose tissue, amniotic membrane, peripheral blood and/or synovial tissue.

Stem cell transplantation using hematopoietic stem cells for treatment of blood cancer, non-cancer conditions and solid tumors are not in scope of this policy.

Coverage Policy

Stem cell therapy as treatment of orthopaedic and/or musculoskeletal conditions, is considered experimental, investigational or unproven for ALL indications, including the following:
regeneration and/or repair of musculoskeletal tissue (e.g., ligament, tendon, and/or meniscus repair, muscle sprain, tendonitis, epicondylitis)
• treatment of joint disease (e.g., articular cartilage repair, joint capsular injury)
• degenerative disc disease (e.g., intervertebral disc repair)
• osteoarthritis (e.g., knee, hip, ankle, shoulder)
• fracture repair, including nonunion of long bone
• osteonecrosis repair

**General Background**

Stem cells are cells that have the ability to differentiate into a number of various cell types and are being used more frequently in the treatment of orthopaedic and/or musculoskeletal conditions. There are various types of stem cells which include but are not limited to embryonic, mesenchymal, and hematopoietic. Embryonic stem cells are isolated from embryonic tissue, while both mesenchymal and hematopoietic are isolated using adult bone marrow. While some stem cells are restricted to a few lineages others may differentiate into a wide variety of cell types. Hematopoietic stem cell transplantation is the only stem cell therapy well-established in clinical practice (Gepstein, Skorecki, 2020).

According to the U.S. National Institute of Health (NIH), regenerative medicine is defined as “the process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects” (NIH, 2010). In general, cellular therapies are purported to produce a regenerative effect by promoting growth and differentiation of local cells. In addition, stem cells possess paracrine and immune-modulating effects through growth factor and cytokine release. Theoretically, stem cells inhibit the release of pro-inflammatory cytokines and promote the survival of existing cells and the repair of damaged tissue.

Within orthopaedics, mesenchymal stem cells are derived mainly from bone marrow, however other sources include adipose tissue (i.e., lipoaspirate), umbilical cord tissue, amniotic fluid, and other extra-articular sources. Mesenchymal stem cells (MSCs) are adult-derived, undifferentiated, multipotent cells that express a variety of different cell surface proteins and can differentiate into a variety of lineages, such as adipogenic (fat cells), osteogenic (bone cells), and chondrogenic (cartilage cells). Adult MSCs do not reach pluripotency, pluripotency is the ability to differentiate into all cell types derived from three germ layers (i.e., ectoderm, mesoderm, endoderm) of the developing embryo (e.g., embryonic stem cell). If MSCs are placed within normal healthy bone, cartilage, or adipose tissue, the stem cells differentiate into that particular tissue. In theory, this property applies to all mesenchymal tissues, including muscle, tendon, and fibrous tissues. MSCs demonstrate little to no ability however to differentiate into nonmesenchymal tissue (e.g., neural or hepatic cells) (Cook, Young, 2019).

MSCs are immunosuppressive and as such do not result in host rejection. One of the proposed advantages of autologous MSCs is the ability to isolate them, expand them in vitro and deliver them as autologous therapy. Nevertheless both autologous and allogeneic MSCs are being used as therapy to treat various orthopaedic conditions. Although processing techniques vary, and the optimal number of MSCs to be transplanted/seeded has yet to be established, MSCs can be concentrated for direct injection, or they be cultured and incubated. Once cultured MSCs can be mixed with other materials such as gels or pastes, or they can be seeded onto scaffolds and used as a support matrix for implantation. Seeded scaffolds have been investigated as a tissue-engineering method within the musculoskeletal system for bone and cartilage repair. However, stem cells may undergo malignant transformation (Wang, et al., 2012) and there is some concern that autologous MSCs may induce tumors by changing the action of cancer cells and accelerating tumor growth, and that allogeneic MSCs may accelerate infectious risk (Wang, et al., 2018).

The steps involved in processing MSCs include harvesting the cells from bone marrow or lipoaspirate, isolation of the cells, followed by proliferation in a culture medium (i.e., culture expanded). Following proliferation the MSCs are stored using cryopreservation. Other manufacturing procedures can be done that avoid cellular isolation and proliferation (i.e., nonexpanded cells) although the resulting number of stem cells within these products are unknown.
Treatment modalities for orthopaedic and/or musculoskeletal conditions proven safe and effective in the peer-reviewed medical literature include the use of pharmaceutical agents, weight loss, physical therapy and exercise, acupuncture, chiropractic care, and surgical repair when all other treatment options have failed. Stem cell therapy is an emerging technology that authors assert may be considered an alternative treatment modality and that may for some individuals avoid future surgical procedures (e.g., knee arthroplasty).

Please reference the Cigna Medical Coverage Policy 0118 Bone, Cartilage and Ligament Graft Substitutes for information regarding demineralized bone matrix (DBM) and other products containing viable stem cells used to enhance healing of bone and 0507 Autologous Platelet-Derived Growth Factors (Platelet-Rich Plasma [PRP]) for use of PRP for orthopaedic indications.

**Literature Review:** Areas undergoing current investigation for the application of MSCs include but are not limited to regeneration and/or repair of musculoskeletal tissue, for example muscle, ligament, tendon, meniscus repair (Chew, et al., 2017; Lin, et al., 2017; Pas, et al., 2017b; Centeno, et al., 2018a; Matsukura, et al., 2014; Centeno, et al., 2015; Vangsness, et al., 2014); treatment of joint disease, including, cartilage lesions, degenerative joint disease, and joint capsular injury (Ha, et al., 2019; Park, et al., 2017; Lee, Wang, 2017; Goldberg, et al., 2017; Filardo, et al., 2013; Ganji, Hauzeur, 2009); osteoarthritis of the knee, hip, ankle, and shoulder (Delanois, et al., 2019; Migliorini, et al., 2019; Emade din, et al., 2018; Jevo tovsky, et al., 2018; Centeno, et al., 2018b; Vannabouathong, et al., 2018; Pas, et al., 2017a; Cui, et al., 2016; Burke, et al., 2016; Vega, et al., 2015; Centeno, et al., 2014; Mobasher, et al., 2014; Koh, et al., 2013; Pak, 2011); epicondylitis (Ahmad, et al., 2012); fracture, including nonunion (Centeno, et al., 2011); and various spinal conditions such as spinal cord injury and intervertebral disc repair (Khan, et al., 2017).

The body of evidence in the published peer reviewed scientific literature evaluating MSCs for treatment of these conditions is mainly in the form of preliminary animal studies, case reports, case series, nonrandomized comparative trials, a number of systematic reviews/meta-analysis, and few randomized trials. The type/source of stem cell used and methods of extraction vary across studies, sample populations are small, reported outcomes are < two years in most studies, and injections include use of other components in some studies, such as hyaluronan or platelet rich plasma making it difficult to attribute the sole effect of MSCs as a treatment response. Regeneration and tissue remodeling has not been firmly established in well-designed, controlled studies and extraction and concentration methods, infusion procedures, indications for use are not standardized, and the optimal source of MSC including the quantity of cells to inject have not been firmly established. Additional RCTs evaluating long term outcomes are needed to firmly establish safety and efficacy of MSCs used for treatment of orthopaedic and/or musculoskeletal conditions. It is not yet proven that a clinical benefit outweighs potential harm that may be associated with MSC therapies.

Information available on the National Institutes of Health website regarding clinical trials indicates that several registered trials of MSCs for the treatment of osteoarthritis, tendon regeneration and other orthopaedic conditions are being conducted and few have been completed. The cells used within these trials include both expanded and nonexpanded MSCs for the treatment of a variety of orthopaedic and/or musculoskeletal conditions.

Some of the more commonly reported conditions under investigation include the following:

**Meniscal Repair:** The meniscus has poor intrinsic healing capacity. Use of stem cells for meniscal injuries has been performed in animals with few studies evaluating use in human meniscal injuries. A concern reported in the literature is the difference in mechanical properties in comparison with native meniscal tissue as well as differences in the extracellular matrix (Chew, et al., 2017). The presence of MSCs in synovial fluid following meniscal injury has been studied (Matsukura, et al., 2014). In comparison to normal knees MSCs were found to be present in higher numbers in synovial fluid with meniscus injury than normal knees. The authors postulated the presence of MSCs in synovial fluid contributed to spontaneous healing of the meniscus, and that additional studies are needed to determine if interventions that increase quantity of MSCs further promote meniscus healing.

MSCs as treatment of meniscal injury involves either intraarticular injection or local delivery to the site using a seeded scaffold. A randomized controlled trial published by Vangsness, et al. (2014) involved 55 subjects who
underwent partial medial meniscectomy (across seven facilities) and were randomized to one of three treatment groups: Group A, in which patients received an injection of $5 \times 10^6$ allogeneic mesenchymal stem cells; Group B, $150 \times 10^6$ allogeneic mesenchymal stem cells; and the control group, a sodium hyaluronate (hyaluronic acid/hyaluronan) vehicle control. Injection was given seven to 10 days following surgery. MSCs were cultured ex vivo and not human leukocyte antigen matched. Clinical outcomes were followed for two years and included safety, meniscal regeneration, and the overall condition of the knee joint. Knee pain was reported using VAS and Lysholm knee scales. Using VAS subjects who received MSC injections had a significant reduction in pain compared with the controls. MRI demonstrated a significant increase in meniscal volume, defined as a >15% threshold, in 24% (3 subjects) of subjects in Group A at two years indicating tissue regeneration according to the authors. A total of 427 adverse events were reported, 272 were mild, 126 were moderate, 28 were severe, and one was life threatening (heart attack one year post procedure). The most common adverse events were arthralgia, joint swelling, joint stiffness, injection-site joint pain, joint effusion, headache, and peripheral edema. Serious adverse events were deemed unlikely to be related to the treatment. The study is limited by small sample population, differences in MRI scans across facilities, and lack of control for osteoarthritis across groups as noted by the authors.

Osteonecrosis: Osteonecrosis is a progressive disease involving the death of bone tissue due to an impaired vascular supply (Hayes, 2015). Osteonecrosis of the femoral head leads to femoral head collapse and need for subsequent hip arthroplasty. The implantation of stem cells into the necrotic lesion of the hip, resulting from osteonecrosis, has been studied in the medical literature as a method of preserving the femoral head. However, studies are in early stages and bone repair originating from the injected cell therapy has not been firmly established. In one preliminary study Pak (2011) reported the results of a series of case reports evaluating the potential of adipose derived MSCs to regenerate bones in human osteonecrosis. Within this study adipose MSCs were combined with additives such as hyaluronic acid, platelet rich plasma and calcium chloride and injected into the osteonecrotic hip of two subjects and knees of two subjects with OA of the knee. MRI results revealed bone formation and cartilage formation three months post treatment however additional studies are needed to support regeneration was attributed to the MSCs.

Knee Osteoarthritis: The bulk of evidence surrounding stem cell use for orthopaedic conditions has focused on regenerating cartilage for individuals with osteoarthritis. Stem cells can be either injected directly into the defect of seeded onto a scaffold providing mechanical support. A systematic review published by Pas et al. (2017a) evaluated stem cell injections for treatment of knee osteoarthritis. A total of five randomized controlled trials (RCT) and one non RCT met inclusion criteria and were included as part of the review. Inclusion criteria were published and unpublished trials, subjects with any degree of osteoarthritis of the knee, stem cells of any origin compared with any other intervention, a minimal proof of stem cell count/typing, and patient reported outcomes for pain, a validated imaging scoring system and/or adverse events. There was no restriction of time, language or content. In all studies bone-marrow-derived stem cells, adipose-derived mesenchymal stem cells and/or peripheral blood stem cells were used. The number of subjects injected with stem cells ranged from 15 to 36; 155 in total were treated with stem cells and 155 served as controls across all studies. In one trial subjects received a total of eight injections, in five trials subjects received only one injection of MSCs. Subjects in five RCTs received injections of platelet rich plasma (PRP) and/or hyaluronic acid (HA) at the same time as MSCs; HA and PRP were also used as monotherapy for the control groups. In two trials uncultured MSCs were used. The authors noted all trials were at high risk of bias, resulting in level-3 evidence. All five RCTs reported superior efficacy for patient-reported outcomes (Visual Analogue Scale, Western Ontario and McMaster Universities Arthritis Index, Tegner, Lysholm, International Knee Documentation Committee, Knee Injury and Osteoarthritis Outcome Score, Lequesne) compared with controls at final follow-up which ranged from 24–48 months. No serious adverse events were reported. Superior radiological outcomes were found favoring stem cell injection. The authors concluded however in the absence of high level evidence stem cell injections for treatment of knee OA is not recommended.

Cui and colleagues (2016) published the results of a meta-analysis evaluating the efficacy of stem cell therapy in treating patients with osteoarthritis. A total of 18 clinical trials met the inclusion criteria, 10 single-arm prospective studies (sample range of 5-41), four quasi-experimental studies (sample range of 18-56), and four RCTs (sample range 50-56). The MSCs utilized were bone marrow-derived, adipose derived and/or peripheral blood stem cells, some in addition to an activation agent (e.g., collagen matrix, adipose tissue, platelet rich plasma). Follow-up within these trials ranged from three to 24 months. Various outcome measurements included International Knee
Documentation Committee (IKDC) scores, Visual Analog Scores (VAS), Tegner and Lysholm scores, and Western Ontario and McMaster Universities OA Index (WOMAC) scores. Compared with pretreatment a pooled effect size was reported as 1.81 at 24 months, with all prior follow-up trending upward, favoring MSC treatment for reducing pain and improving function. A dose related response was unclear regarding the number of MSCs used in treatment. Using only the data from the RCTs MSC treatment was not found to be superior. Transient regional pain and local swelling were the predominant adverse events reported (7 trials) and none of the patients were diagnosed with cancer associated with MSC use. Limitations of the study include small sample size, lack of long term follow-up, varying doses of MSCs, and the addition of activation agents, which also varied among trials.

Vega et al. (2015) reported the results of a RCT evaluating bone marrow-derived MSCs as treatment for osteoarthritis of the knee. All subjects had chronic knee pain and failure of other conservative measures. The control group (n=15) received intra-articular hyaluronic acid while the experimental group (n=15) received intra-articular injections of allogenic bone marrow-derived MSCs. Clinical outcomes were followed for one year and included assessment of pain, disability and quality of life and MRI for assessing cartilage quality. At one year follow-up the treatment group demonstrated decreases in poor cartilage areas, improved quality of cartilage and pain relief. The effects were significant at both 6 and 12 months for MSC treated subjects. The authors noted their results in comparison with other results for autologous bone marrow-derived MSCs was smaller, and for autologous adipose- derived MSCs was similar. The study is limited by short term follow-up and small sample size.

In addition to these and other studies, several systematic reviews and meta-analyses have been published. Although some conclusions support improvement in pain and function for some individuals, limitations such as heterogeneity of inclusion and exclusion criteria, lack of controls, MSC therapies which have been applied in different stages of osteoarthritis, the use of various quantities of MSCs, and lack of long term outcomes prohibit strong evidence based conclusions regarding clinical safety and efficacy.

Muscle/Tendon/Ligament Repair: Stem cell therapy as treatment of tendon and ligament disorders is also an emerging field. Similar to other musculoskeletal tissues tendons and ligaments possess poor regenerative capability. There is a paucity of studies evaluating the efficacy of stem cell therapy for tendon/ligament healing. A systematic review evaluating the evidence for the use of stem cell therapy for tendon disorders was published by Pas, et al., 2017(b). A total of four published trials and three unpublished/pending trials were included in the review (n=79). Two of the trials evaluated bone marrow stem cells injected for treatment of rotator cuff repair, one trial used allogenic adipose derived stem cells for treatment of epicondylar tendinopathy and one trial evaluated bone marrow derived stem cells for treatment patellar tendinopathy. According to the authors all trials were high risk of bias and level four evidence. Absence of controls limited interpretation regarding any benefit. With the exception of the trial using adipose derived stem cells none of the trials using bone marrow MSCs performed cell culturing or cell typing. In epicondylar tendinopathy, patellar tendinopathy and rotator cuff repairs improved healing, functional outcomes and pain scores were reported compared with baseline. Re-rupture of repaired rotator cuffs treated with stem cells preoperatively were reduced in comparison with historical controls or other literature. Only one trial reported adverse events, safety concerns remain. Reporting of cell analysis was inconsistent among trials and it is unknown what if any effect cell dose had. The authors concluded the evidence was insufficient to support the use of stem cell therapy for treatment of tendon disorders.

Because of their multipotent potential and ability to exert paracrine effects and potential to improve blood flow mesenchymal stem cells have been studied as a treatment of rotator cuff disease (Lin, et al, 2017). Rotator cuff repairs occur most commonly at the tendon-bone interface. During repair, reattaching the tendon to the bone is challenging due to various physiological reasons, often resulting in frequent failure. Nevertheless, there is a paucity of evidence evaluating the effect of MSC therapy for rotator cuff disease and outcomes demonstrating improved healing are inconsistent.

U.S. Food and Drug Administration (FDA)
Medical and surgical procedures do not require FDA approval. In addition, the use of concentrated, autologous mesenchymal stem cells (MSCs) do not require FDA approval. The FDA does regulate human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. Currently there are no allogenic MSC materials
using engineered or expanded MSCs approved by the FDA for orthopaedic applications (Cook, Young, 2019). According to the FDA, “the only stem cell-based products that are FDA-approved for use in the United States consist of blood-forming stem cells (hematopoietic progenitor cells) derived from cord blood”. Safety concerns of the FDA regarding the use of unproven stem cells include administration site reactions, failure of cells to work as expected, the growth of tumors, and the ability of cells to move from placement sites and change into inappropriate cell types and multiply.

**Regenexx®:** Regenexx® (Des Moines, Iowa, [previously known as Regenerative Sciences]) “regenerative” procedures (e.g., RegenexxSD® [Same Day Stem Cell Procedure], RegenexxAD® [Adipose Derived Stem Cell Procedure]), have been recommended for treatment of musculoskeletal trauma, overuse injuries, and degenerative issues. During Regenexx® procedures, cells of various derivatives, often from bone, are injected to locally diseased joint areas with the expectation that they will seek out and repair diseased cartilage bone, ligaments and tendons. According to the manufacturer, the Regenexx- Same Day (SD)/Regenexx-SD Plus procedure involves the injection of a highly concentrated stem cell mixture combined with autologous platelet-derived growth factors, referred to as SCP (Super Concentrated Platelets). It has been proposed for a variety of orthopaedic applications including but not limited to repair or regeneration of musculoskeletal tissue, spinal fusion, and bone repair.

In addition, Regenexx describes a licensed culture-expansion site, Regenexx Cayman that provides Regenexx-C (cultured stem cell treatment) and Regenexx Cryopreservation (stem cell storage). The manufacturer asserts these techniques are reported to yield up to 1,000 times more stem cells. Regenexx-C is stated to be ideal for patients with more severe orthopaedic injuries or conditions, patients who want to treat multiple joints, or patients who want to store their stem cells for future treatment. This procedure is not FDA approved.

One randomized controlled (RCT) was located (Centeno, et al., 2018b) in the peer reviewed scientific literature evaluating Regenexx therapy for knee OA. This study included patients with symptomatic knee osteoarthritis (n=48) who were assigned to either an exercise therapy control group (n=22) or treatment group with image-guided injection of autologous bone marrow concentrate (BMC) and platelet products (n=26). At three months subjects were allowed to crossover to the bone marrow treatment group. Measured outcomes included the Knee Society Score (KSS), Pain Visual Analogue Scale, Short Form-12 Scales (SF-12), and Lower Extremity Activity Scale (LEAS). Follow-up for clinical outcomes occurred at 6-weeks, 3, 6, 12 and 24 months. A total of 14 patients were lost to follow-up. All 22 patients in the control group crossed over to BMC treatment after three months. Patients who received a specific protocol of BMC and platelet products improved significantly in activity levels, as well as pain, range of motion and stability, compared to patients who underwent a home exercise therapy program for 3 months. Pain decreased for both the exercise therapy and the BMC groups, and function increased for the BMC group, although did not differ significantly between the 2 groups. Exercise therapy provided significant improvements in ROM and activity levels at 3-months compared to baseline. No serious adverse events were reported. Limitations of this RCT include the small sample size and the allowance of those in the exercise group to crossover at three months and receive BMC. Additional controlled studies with larger sample sizes evaluating Regenexx processes/procedures/products are needed to support safety and effectiveness.

The overall body of evidence indicates that safety and efficacy of Regenexx procedures, including BMC with platelet rich plasma and other lysate preparations, are currently unproven. Although the body of evidence is emerging, concerns regarding quality and oversight, preparation, application/procedure, safety, clinical utility, and durability have been reported among authors.

**Cartistem®:** Cartistem® is a combination of human umbilical cord blood-derived mesenchymal stem cells and sodium hyaluronate, and is intended to be used as a single-dose therapeutic agent for cartilage regeneration in humans with cartilage defects of the knee as a result of aging, trauma, or degenerative diseases (National Institute of Health, Clinicaltrials.gov NCT01733186). Although results have not yet been published, according to ClinicalTrials.gov a study is underway evaluating the efficacy and safety of Cartistem®.

**Lipogem®** Microfragmented Adipose Tissue Transplant System (Lipogem, Norcross, GA) is an adipose-derived regenerative cell therapy described by the manufacturer as closed circuit processing system used to remove adipose tissue from the body and transfer it via injection into a patients injured joint or diseases
soft tissue. It is asserted Lipogems preserves the structural properties and microarchitecture of the original tissue: the scaffold (the adipose tissue and the stromal structure), the cells (endothelium, pericytes / MSCs), and the growth factors (cytokines and chemokines. Lipogems received FDA 5109k) approval in 2016 as a suction lioplasty system. It is noted with the 510(k) approval the device is intended for use in the following surgical specialties when the transfer of harvested adipose tissue is desired: orthopaedic surgery, arthroscopic surgery, neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, general surgery, gynecological surgery, thoracic surgery, laparoscopic surgery, and plastic and reconstructive surgery when aesthetic body contouring is desired (FDA, K161636). Panchal et al (2017) reported on 17 subjects with osteoarthritis of the knee who underwent Lipogem injection intra-articularly under ultrasound guidance. Pre and post treatment outcomes were collected at six weeks, six months and 12 months following therapy using NPRS (numerical pain rating scale), the 100-point Knee Society Score (KSS) and lower extremity activity scale (LEAS). Although the authors reported significant improvements in MPRS, mean KSS at 12 months the study is limited by small sample population, lack of control, and short term outcomes.

In 2019 Hayes, Inc. published an evidence analysis research brief evaluating the use of autologous micro-fragmented adipose tissue (MFAT) injection for treatment of degenerative joint disease (DJD). The review included nine abstracts, including 1 randomized controlled trial (RCT), 3 prospective uncontrolled studies, 3 reports of 2 retrospective uncontrolled studies, and 2 commentaries. The Lipogems system was used in one study, others did not report the source of MFAT. Hayes concluded that overall the findings are conflicting for improvement of health outcomes, and until reviewed further conclusions regarding the safety and effectiveness could not be made. Additional studies are underway, however at present there is insufficient evidence in the peer reviewed scientific literature to support safety and efficacy of Lipogems for treatment of knee osteoarthritis or other orthopaedic /musculoskeletal conditions.

Professional Societies/Organizations
The American Academy of Orthopaedic Surgeons (AAOS) does not take a position for or against the use of stem cell therapy for orthopaedic applications, however within a position statement regarding the use of emerging biologic therapies (AAOS, 2017) the AAOS states the following: “Surgeons must be aware of the scientific basis for the different treatment options offered to their patients, including benefits and risks. The varying regulatory pathways by which biologic therapies come to market require the additional burden for surgeons to become familiar with the Food and Drug Administration’s current thinking with respect to the source, retrieval and/or manufacturing methods, processing, storage, and use of these products, whether alone or as part of combination products.

The American Academy of Orthopaedic Surgeons (AAOS) believes that surgeons should be cognizant of the risks, benefit, regulatory status and labeled indications of the products they use. Unlike devices, the effects of these products may not be limited to the duration of their implantation. Autogenous products may be subject to regulatory review” (AAOS, 2017).

The International Society of Stem Cell Research (ISSCR) published information regarding stem cell types and uses (ISSCR, 2019) and asserts there is little evidence they are beneficial. MSC therapy remains in early experimental stages. According to ISSCR, mesenchymal stem cells are cells that originate from stroma, the connective tissue surrounding tissues and organs. Although various MSCs are thought to have stem cell and immunomodulatory properties as treatment for various disorders. Scientists do not fully understand whether these cells are actually stem cells or what types of cells they are capable of generating. They do agree that not all MSCs are the same, and that their characteristics depend on where in the body they come from and how they are isolated and grown. Some types of stem cells are capable of migration after transplantation, meaning there is a risk of off-target effects and inappropriate integration.

Centers for Medicare & Medicaid Services (CMS)
- National Coverage Determinations (NCDs): Not found.
- Local Coverage Determinations (LCDs): Not found.

Use Outside of the US
No relevant information found.
Coding/Billing Information

Note: 1) This list of codes may not be all-inclusive.
       2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Experimental/Investigational/Unproven:

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20999</td>
<td>Unlisted procedure, musculoskeletal system, general</td>
</tr>
<tr>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td>0565T</td>
<td>Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation</td>
</tr>
<tr>
<td>0566T</td>
<td>Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral</td>
</tr>
</tbody>
</table>

Considered Experimental/Investigational/Unproven when used to report stem cells used as treatment of orthopaedic and/or musculoskeletal conditions:

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P9099</td>
<td>Blood component or product not otherwise classified</td>
</tr>
</tbody>
</table>


References


75. Wang Y, Han ZB, Song YP, Han ZC. Safety of mesenchymal stem cells for clinical application. Stem Cells Int. 2012;2012:652034.